What the FDA labels say about taking them together
Fluorescein and loteprednol
Loteprednol's FDA label (Eysuvis) of March 11, 2025 names fluorescein in its warnings and precautions section; the fluorescein labels PlainMeds reads (2) do not name loteprednol. The loteprednol label: “… of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. Intraocular Pressure (IOP) Increase:”
Check it at the source: the fluorescein FDA label on DailyMed (effective February 26, 2026, Long Grove Pharmaceuticals, LLC); the loteprednol FDA label on DailyMed (effective February 7, 2026, Bausch & Lomb Americas Inc.).
What does the fluorescein label say about loteprednol?
Fluorescein's label (effective February 26, 2026) and its 1 other brand-application label do not name loteprednol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AK-FLUOR), Long Grove Pharmaceuticals, LLC, effective February 26, 2026 (SPL set 73511e79-c050-4dc0-aa2f-a79ed320b5b0), via openFDA; the full label on DailyMed
What does the loteprednol label say about fluorescein?
Eysuvis label (ALCON LABORATORIES, INC., March 11, 2025), warnings and precautionsWARNINGS AND PRECAUTIONS Delayed Healing and Corneal Perforation :The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. ( 5.1 ) Intraocular Pressure (IOP) Increase:
Lotemax Sm label (Bausch & Lomb Incorporated, March 31, 2026), warnings and precautionsThe initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. ( 5.3 ) Bacterial infections – Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.
Source: FDA drug label (Eysuvis, NDA210933), ALCON LABORATORIES, INC., effective March 11, 2025 (SPL set a2169d82-4275-4ab6-a1c3-c274080b815c), via openFDA
Source: FDA drug label (Lotemax Sm, NDA208219), Bausch & Lomb Incorporated, effective March 31, 2026 (SPL set 6f9477b5-699f-4d3b-b9a6-0cc238266237), via openFDA
Source: FDA drug label (loteprednol etabonate), Bausch & Lomb Americas Inc., effective February 7, 2026 (SPL set 7714824b-29ed-442a-ad2d-13ee2fc6bc42), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluorescein | Loteprednol | |
|---|---|---|
| Labeled for | n/a | Pain |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $10.47 per mL 0.5% drp |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once